# GSK plc (GSK)

> Source: Nexqual · https://nexqual.com/GSK · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, GSK plc (GSK), nexqual.com/GSK" · informational, not investment advice.

**Price:** USD 51.21 (+2.38% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 50.02 · day 49.97–51.44 · 52w 42.85–61.7 · market cap $103B · NYQ

## Key facts
- 6 of 80 tracked superinvestors hold GSK (13F, Q2 2026): 0 new, 1 added, 4 reduced, 1 unchanged.
- Analysts: Hold (mean 2.56 on a 1–5 scale) (9 analysts), mean target USD 60.51 (range 49–70).
- Total return with dividends: 1Y +16.4% vs S&P 500 +14.9%; 5Y +57.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.33, revenue estimate $8.81B.

## Superinvestors (SEC 13F-HR, Q2 2026)
6 of 80 tracked investors hold GSK. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 3.51% | $4.8M | Reduced -5.2% |
| Kahn Brothers | Kahn Brothers Group | 1.58% | $8.9M | Unchanged |
| Dodge & Cox Funds | Dodge & Cox | 1.32% | $2.53B | Reduced -17.8% |
| Tweedy Browne |  | 0.32% | $4.3M | Reduced -0.3% |
| Richard Pzena | Pzena Investment Management | <0.01% | $1.3M | Added +30.2% |
| Sarah Ketterer | Causeway Capital Management | <0.01% | $375K | Reduced -35.5% |

## Analysts
Consensus Hold (mean 2.56 on a 1–5 scale), 9 analysts; mean target USD 60.51 (low 49, high 70).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +16.4% | +57.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +16.5% | +9.5% |
| Volatility (annualized) | 26.3% | 23.6% |
| Max drawdown | -22.4% (Feb 2026→Oct 2026) | -35.8% (Apr 2022→Sep 2022) |

## Peers (Drug Manufacturers - General)
SNY (Sanofi) USD 41.96 +2.42% · BMY (Bristol-Myers Squibb Company) USD 63 +3.08% · PFE (Pfizer, Inc.) USD 30.42 +1.91% · NVO (Novo Nordisk A/S) USD 39.43 +0.95% · GILD (Gilead Sciences, Inc.) USD 157.19 +2.36% · AMGN (Amgen Inc.) USD 447.28 +2.04%

## More
Full page: https://nexqual.com/GSK · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.33 | $1.41 | -6.1% | $8.81B | 2 |
| Next quarter (ends 2026-12-31) | $0.77 | $0.81 | -4.1% | $8.96B | 2 |
| Current fiscal year (ends 2026-12-31) | $4.72 | $4.79 | -1.4% | $33.90B | 5 |
| Next fiscal year (ends 2027-12-31) | $4.92 | $5.13 | -4.0% | $35.51B | 5 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-10-30 (includes earnings 2026-10-28): ±5.6%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-10-30 | 7 | 46.9% | ±5.6% |
| 2026-11-06 | 14 | 35.2% | ±5.7% |
| 2026-11-13 | 21 | 31.9% | ±6.6% |
| 2026-11-20 | 28 | 29.7% | ±6.8% |
| 2026-11-27 | 35 | 28.5% | ±7.2% |
| 2026-12-18 | 56 | 27.9% | ±8.8% |
| 2027-01-15 | 84 | 25.9% | ±10.0% |
| 2027-02-19 | 119 | 26.9% | ±12.5% |